Study on the Impact of the Centralized Drug Procurement Policy on the Distribution of Oral Antidiabetic Drugs Among Different Levels of Medical Institutions

doi:10.19546/j.issn.1674-3830.2026.7.013

China Health Insurance ›› 2026, Vol. 0 ›› Issue (7) : 103-111. DOI: 10.19546/j.issn.1674-3830.2026.7.013

Author information +

History +

Abstract

Objective: The paper attempts to evaluate the impact of the centralized drug procurement (CDP) policy on the distribution of oral antidiabetic drugs across different levels of medical institutions. Methods: Utilizing drug procurement data from a provincial database from 2018 and 2024, an interrupted time series analysis was conducted to compare the immediate level changes and long-term trend changes in the proportion of Defined Daily Doses for different drug categories between primary and secondary medical institutions before and after the policy implementation. Results: Following the CDP policy, the trend of most traditional oral antidiabetic drugs shifting toward secondary hospitals significantly increased. Among novel oral antidiabetic drugs, only a subset of centrally procured oral antidiabetic drugs showed a shift toward lower-level healthcare institutions. Conclusion: The CDP policy effectively promoted the redistribution of some traditional oral drugs towards lower-level medical institutions, but its effect on novel antidiabetic drugs requires reinforcement. Future policy refinements should consider optimizing the scope of drug selection, thereby better facilitating rational drug use and promoting the hierarchical diagnosis and treatment.

Key words

centralized drug procurement / antidiabetic drugs / interrupted time series analysis / hierarchical diagnosis and treatment

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Study on the Impact of the Centralized Drug Procurement Policy on the Distribution of Oral Antidiabetic Drugs Among Different Levels of Medical Institutions[J]. China Health Insurance. 2026, 0(7): 103-111 https://doi.org/10.19546/j.issn.1674-3830.2026.7.013

References

[1] 国务院办公厅.关于推动药品集中带量采购工作常态化制度化开展的意见[EB/OL].(2021-01-28)[2026-04-18].https://www.gov.cn/zhengce/content/2021-01/28/content_5583305.htm.
[2] Chen Y, Ji X, Xiao H, et al.Impact of the pilot volume-based drug purchasing policy in China: Interrupted time-series analysis with controls[J]. Frontiers in Pharmacology, 2021, 12: 804237.
[3] International Diabetes Federation. IDF Diabetes Atlas, 11th edition[R/OL]. Brussels, Belgium: International Diabetes Federation, (2025)[2026-04-18]. https://diabetesatlas.org/.
[4] Wang B, Xiao K, Xia H, et al.The impacts of the national volume-based procurement policy on the chronic disease medication market in China’s public hospitals: a case study of medications for diabetes[J]. BMC Health Services Research, 2025, 25(1): 1279.
[5] Song J, Guo W, Jin C, et al.Analysing the effects of National Centralised Drug Procurement and Price Negotiation Policies on novel hypoglycaemic drug usage and costs in Shanghai, China: an interrupted time series analysis[J]. BMJ open, 2024, 14(12): e088318.
[6] 胡红岩,穆耕林,曹红梅,等.药品集中带量采购对糖尿病患者住院费用的影响[J].中国卫生资源,2023,26(02):163-166+183.
[7] 中华医学会糖尿病学分会.中国糖尿病防治指南(2024版)[J].中华糖尿病杂志,2025,17(1):16-139.
[8] Ceriello A, Colagiuri S.IDF global clinical practice recommendations for managing type 2 diabetes-2025[J]. Diabetes Research and Clinical Practice, 2025, 222: 112152.
[9] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.
[10] 曾大勇,王飞羽,林荣芳,等.基于全国药品使用监测数据的降糖药物利用情况分析[J].中国现代应用药学,2025,42(10):1754-1761.
[11] Cao W, Feng H, Yang Y, et al.Trends in antidiabetic drug use and expenditure in public hospitals in Northwest China, 2012-21: a case study of Gansu Province[J]. BMC Health Services Research, 2024, 24(1): 415.
[12] WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index2025[EB/OL]. (2024-12-27)[2026-04-18]. https://atcddd.fhi.no/atc_ddd_index/.
[13] 上海市卫生健康委员会.关于印发《上海市医疗机构设置规划(2021-2025年)》的通知[EB/OL].(2021-10-22)[2026-04-18]. https://wsjkw.sh.gov.cn/zxghjh/20211022/50bb0973811b44469af11e55bd983e95.html.
[14] 赵加奎,杨文洁,董玉婷,等.信任状况与患者就医行为、门诊费用及健康教育需求的相关分析[J].中国健康教育,2022,38(07):622-626.
[15] 滕明悦. 差异化医保报销政策对参保人就医选择的影响研究[D].济南:山东大学,2024.
[16] Tang W, Li W, Lu W, et al.Availability, prices and affordability of nationally negotiated antidiabetic medicines in China: a national survey[J]. BMC Health Services Research, 2026.
[17] 卢立,彭偲偲,程静,等.2018—2021年武汉地区33家医疗机构降糖药物使用情况分析[J].医药导报,2023,42(10):1553-1560.
[18] 杨燕,吴文辉,汤庆伟,等.基于药品采购数据库的上海市各级医疗机构降糖药物利用情况分析[J].中国卫生经济,2017,36(03):53-56.
[19] 国家卫生健康委员会.关于改革完善基层药品联动管理机制扩大基层药品种类的意见[EB/OL].(2024-11-14)[2026-04-18]. https://www.gov.cn/gongbao/2025/issue_11846/202502/content_7002778.html.
[20] 国务院办公厅.关于推进分级诊疗制度建设的指导意见[EB/OL]. (2015-09-08)[2026-04-18]. https://www.gov.cn/zhengce/content/2015-09/11/content_10158.htm.